fbpx

Grey Wolf Therapeutics completes £2.5 million Series A2 financing to accelerate development of therapies targeting ERAP2

Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for...

Inceputua appoints new president to lead North America business development

Inceptua announced today that Paul Wituschek has been appointed President North America. To further strengthen its position as a leading pharmaceutical company and service partner, Inceptua appoints Paul Wituschek as President North America effective 1 January,...